Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

Clinical trial NCT05733715 · RECRUITING

Trial details

NCT number: NCT05733715
Sponsor: Abramson Cancer Center at Penn Medicine
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Renal Cell Carcinoma

Start date: 2023-05-03
Primary completion: 2028-04-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.